Special drug use survey of Tremfya for Psoriasis

Special drug use survey of Tremfya for Psoriasis - TRM1L

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032969

Enrollment

400

Registered

2018-06-13

Start date

2018-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis, Psoriatic arthritis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who initiate Tremfya in accordance with the indication in package insert. [Indications] The following diseases which do not adequately respond to conventional treatments; Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis

Exclusion criteria

Exclusion criteria: Patients with a history of the use of ustekinumab (active ingredient of this product)

Design outcomes

Primary

Measure	Time frame
Variables related to safety a.Data on adverse reactions/infection b.Data on serious adverse events c.Data on adverse reactions of primary survey items d.Factors possibly affecting the safety e.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder) f.Data on adverse reactions of malignancy after long term of administration Variables related to efficacy a.Data on adverse reactions/infection b.Data on serious adverse events c.Data on adverse reactions of primary survey items d.Factors possibly affecting the safety e.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder) f.Data on adverse reactions of malignancy after long term of administration	—

Measure

Time frame

Variables related to safety a.Data on adverse reactions/infection b.Data on serious adverse events c.Data on adverse reactions of primary survey items d.Factors possibly affecting the safety e.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder) f.Data on adverse reactions of malignancy after long term of administration Variables related to efficacy a.Data on adverse reactions/infection b.Data on serious adverse events c.Data on adverse reactions of primary survey items d.Factors possibly affecting the safety e.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder) f.Data on adverse reactions of malignancy after long term of administration

—

Countries

Japan

Contacts

Public ContactKeiko Imai

Janssen Pharmaceutical K.K. Medical Affiars Delivery Unit

kimai4@ITS.JNJ.com+818023618773

Outcome results